Driving change for better health at Novo Nordisk Pharma Day® 2024
Sep 03, 2024
MassBio is partnering with Novo Nordisk on October 29, 2024, to host Novo Nordisk Pharma Day® 2024. MassBio’s Pharma Days® are unparalleled opportunities for emerging innovators to learn from and connect with world-leading biopharmaceutical companies. Novo Nordisk, founded in 1923 and headquartered in Denmark, is a leading global healthcare company that is driving change to defeat serious chronic diseases by pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease.
“As one of the most important innovation ecosystems in the industry, the Greater Boston area is also an important hub for Novo Nordisk, and we look forward to connecting with some of its leading pioneers at the Novo Nordisk Pharma Day. We believe that by combining innovative ideas with the experience of bringing them to life, we can create more value together than we each could alone.
We are open to all forms of partnering – from collaborations to licenses and acquisitions – especially in Diabetes and Obesity, as well as Cardiovascular Disease and Rare Blood Disorders. Together as partners, we can pioneer scientific innovation to improve patients’ lives and continue driving change for people living with a serious chronic disease.”
–David Moore, Executive Vice President, Corporate Development, Novo Nordisk
Hear the latest: Join Novo Nordisk’s open information session for the latest insights on its approach to partnering, R&D strategy, and priority therapeutic areas. With a special focus on novel therapeutic approaches to obesity management, the Novo Nordisk team is looking forward to a lively discussion about the future development of the field.
Speakers will include Dave Moore (EVP, Corporate Development), Tamara Darsow (CVP, Corporate Strategy), and John McDonald (CVP, Globel Head of Business Development and M&A), with more being added.
Make a connection: Groundbreaking innovators across early research and discovery stages of development with any therapeutic modality are encouraged to apply for a one-on-one meeting with Novo Nordisk representatives throughout the day on October 29.
Novo Nordisk’s priority therapeutic areas are Diabetes, Obesity, and other Serious Chronic Diseases (Cardiovascular Diseases, MASH/NASH, CKD, Rare Blood Disorders)
If your company meets the eligibility guidelines, apply for a 1:1 by September 16, 2024 at 11:59PM ET.
